Burden of multiple sclerosis in Iran from 1990 to 2017

Nima Fattahi1†, Sahar Saeedi Moghaddam1†, Farnam Mohebi1, Negar Rezaei1,2, Masoud Masinaei1,3, Sahar Mohammadi Fateh1,2, Elham Soleymani Hassanlouei4, Farhad Manoochehri6, Eghbal Fattahi5, Mohammad Ali Sahraian6, Maziar Moradi-lakeh7, Ali H. Mokdad8, Mohsen Naghavi8 and Farshad Farzadfar1,2*

Abstract

Background: Multiple Sclerosis (MS) is a burdensome, chronic and autoimmune disease of the central nervous system. We aimed to report the incidence, prevalence, mortality, and Disability Adjusted Life Years (DALYs) of MS in Iran at a national level for different age and sex groups over a period of 28 years (1990–2017).

Methods: Data were extracted from the Global Burden of Disease study (GBD) from 1990 to 2017, published by the Institute for Health Metrics and Evaluation. The incidence of DALYs and prevalence of MS were estimated to report the burden of MS based on sex and age in Iran from 1990 to 2017.

Results: At the national level, the Age-Standardized Incidence Rate (ASIR), Age-Standardized Prevalence Rate (ASPR), Age-Standardized DALYs Rate (ASDR) and the Age-Standardized Mortality Rate (ASMR) in Iran in 2017 were 2.4 (95% Uncertainty Interval [UI]: 2.1 to 2.7), 69.5 (62.1 to 77.8), 29.1 (23.6 to 34.7), and 0.4 (0.3 to 0.4) per 100,000 population, respectively. During the period of 1990 to 2017, all measures increased, and were higher among females. The incidence rate began upward trend at the age of 20 and attained its highest level at the age of 25.

Conclusion: In Iran, all of the age-standardized MS rates have been increasing during the 28 years from 1990 to 2017. Our findings can help policy makers and health planners to design and communicate their plans and to have a better resource allocation, depending on the incidence and prevalence of the growing numbers of MS patients in Iran.

Keywords: MS (multiple sclerosis), Burden of disease, Iran, Global burden of disease study, Trend

Background

Multiple Sclerosis (MS) is a central nervous system disease that is categorized as an autoimmune and chronic disease that causes nerve damage, inflammation and demyelination of the nerves [1–5]. The disease irreversibly destroys axons and myelin to varying degrees [5, 6]. MS was considered as a T-cell mediated disease with an abnormal balance between regulatory T-cells and Central Nervous System (CNS) reactive effector T-cells. Recently added evidence shifted attention to B cells’ potential contributions on CNS inflammatory disease activity, mainly the antibody-independent functions of B cells implicated in mediating new relapsing MS disease activity as part of cascades of cellular immunological interactions in the periphery [7]. The main cause of the illness is not clearly known, but a few genetic and environmental factors are involved in the onset of the disease, which include positive serology of the nuclear antigen of the Epstein bar virus, infectious mononucleosis and smoking [3]. Other possible causes of the disease include lack of vitamin D intake, genetic risk factors [6], geographical distribution,
so that the studies have shown that MS prevalence and incidence increases with latitude gradient [3, 8]. Regarding diet, hypercaloric Western-style diets, characterized by high salt, animal fat, red meat, sugar-sweetened drinks, fried food, low fiber, and lack of physical exercise are other predisposing factors of MS [9].

Based on the MS International Federation report, the global mean prevalence rate of MS increased from 30 cases per 100,000 population in 2008 to 33 cases per 100,000 population in 2013. The lowest rates of 2 (1.71 to 2.29) and 2.8 (2.4 to 3.1) were seen in Oceania and Central Sub-Saharan Africa, respectively. Conversely, the highest prevalence rates were seen in Nova Scotia (266.9) and British Columbia (179.9) of Canada, and North America (164.6) [1, 4]. Since MS does not lead to quick deaths, reporting other measures in addition to the incidence and prevalence can help better measure the burden of the disease [10]. In this regard, the Disability Adjusted Life Year (DALY) is used as one of the most applicable measures for evaluating community health. In 2013, globally, a total of 1,343,000 DALYs and 1920 ASDR applicable measures for evaluating community health. In 1990 to 2017, a total of 1,343,000 DALYs and 1920 ASDR were mapped to define non-fatality and fatality of MS, respectively [14, 16]. The original data estimated by the GBD for MS in Iran was mostly from death registry system, MS registry and scientific literatures. Rates are expressed as age-standardized based on the GBD reference population [17]. 95% Uncertainty Intervals [18] were calculated with the 2.5th and 97.5th percentiles of 1000 draws by age, sex, location, and year, and point estimates were calculated from the median estimates across the draws for each measure.

Decomposition analysis was applied between 1990 and 2017 to determine the contribution of change in the age-specific incidence rate, population growth, and population aging of new cases [19]. Percent changes for number and rate were calculated as the difference between the last and first study years divided by each measure's initial value. We computed expected burden on the basis of sociodemographic index (SDI) and compared these estimates to observed rates. The SDI is calculated from the geometric mean of total fertility rate under 25 years, lag-distributed income per capita, and average educational attainment in the population older than 15 years [15]. The Mortality-to-Incidence Ratio (MIR) was calculated to measure quality of care and evaluate disease management outcome. Figures were depicted by R version 3.4.2.

**Results**

At the national level, MS related Age Standardized Incidence Rate (ASIR) was 2.0 (95% UI: 1.8 to 2.2) and 2.4 (2.1 to 2.7) per 100,000 population in 1990 and 2017, respectively, with an average annual percentage change of 0.6. The females to male's ratio of ASIR was 1.8 in 1990 and 1.9 in 2017 (Table 1). The age trend of the disease had been shown in the 1990s, 2000s, 2010 and 2017, and followed a similar pattern throughout all these years. The incidence rate began its upward trend from the age of 20 years and peaked at the age of 25. From the age of 25, a downward trend began and reached its lowest level at the ages of 55 to 59 (Fig. 1). The evaluation of the ASIR time trend showed that there had been a slight slope in the period from 1990 to 1995, after which it slightly decreased from 1996 to 2005 and then began to rise from 2005 until 2017 (Fig. 2). The population age pyramid of incidence rate in 1990 and 2017 indicated that the highest incidence rate was in the 25–29 years age group and then followed a downward trend (Fig. 3). Furthermore, decomposition analysis showed that 42.0% of the changes in the disease's incidence cases were due to population growth, 26.2% due to the age structure changes and 34.1% due to changes in the incidence rate of the disease (Table 2).

In Iran, ASPR increased from 55.8 (50.1 to 62.5) per 100,000 people in 1990 to 69.5 (62.1 to 77.8) in 2017, with an average annual percentage change of
| Measure      | Unit          | Location                  | Both 1990 | Both 2017 | Percent change $^c$ | Male 1990 | Male 2017 | Percent change $^c$ | Female 1990 | Female 2017 | Percent change $^c$ |
|--------------|---------------|---------------------------|-----------|-----------|--------------------|------------|-----------|--------------------|--------------|--------------|--------------------|
| Incidence    | Number $^a$   | Global                    | 40,417 (36,731 to 44,787) | 54,895 (50,054 to 60,812) | 35.8 (33.9 to 37.9) | 14,996 (13,365 to 16,691) | 19,930 (18,068 to 22,184) | 32.9 (30.8 to 35.2) | 25,421 (23,138 to 28,110) | 34,964 (31,830 to 38,686) | 37.5 (35.4 to 39.9) |
|              |               | North Africa and Middle East | 3674 (3240 to 4135) | 7740 (6950 to 8646) | 110.7 (102.5 to 120.3) | 1295 (1133 to 1467) | 2713 (2420 to 3049) | 1094 (100.8 to 119.2) | 2379 (2102 to 2681) | 5026 (45.20 to 5600) | 111.3 (102.5 to 121.6) |
|              |               | Iran                      | 1122 (1004 to 1254) | 2271 (2024 to 2557) | 102.3 (90.3 to 117.1) | 390 (347 to 436) | 794 (705 to 894) | 103.7 (91.5 to 117.8) | 73.2 (657 to 821) | 147.7 (1315 to 1666) | 101.6 (89.3 to 117.3) |
| Prevalence   | Number $^a$   | Global                    | 1,048,261 (946,018 to 1,146,731) | 1,761,078 (1,598,226 to 1,947,909) | 68.0 (65.5 to 70.6) | 335,891 (300,256 to 375,033) | 551,872 (498,079 to 614,373) | 64.3 (61.8 to 66.9) | 712,369 (645,599 to 789,379) | 1,209,206 (1,096,303 to 1,336,075) | 69.7 (67.0 to 72.7) |
|              |               | North Africa and Middle East | 71,262 (62,756 to 80,648) | 201,299 (181,311 to 223,278) | 182.5 (174.6 to 191.9) | 23,645 (20,552 to 26,789) | 65,344 (58,438 to 72,850) | 176.4 (168.2 to 185.8) | 47,617 (41,965 to 53,835) | 135,955 (122,509 to 150,603) | 185.5 (176.7 to 195.2) |
|              |               | Iran                      | 21,662 (19,342 to 24,342) | 62,397 (55,554 to 69,871) | 188.1 (179.9 to 196.5) | 7304 (6470 to 8182) | 20,102 (17,828 to 22,498) | 175.2 (167.7 to 183) | 14,358 (12,810 to 16,143) | 42,295 (37,774 to 47,790) | 194.6 (185.1 to 204.6) |
|              | Rate $^b$     | Global                    | 22.5 (20.3 to 24.9) | 21.7 (19.7 to 24.0) | −3.4 (−4.6 to −2.1) | 14.5 (13.0 to 16.2) | 13.8 (12.4 to 15.3) | −5.0 (−6.1 to −3.8) | 30.1 (27.3 to 33.4) | 29.3 (26.6 to 32.4) | −2.5 (−4.0 to −1.0) |
|              |               | North Africa and Middle East | 28.9 (25.6 to 32.7) | 35.8 (32.4 to 39.7) | 23.9 (20.6 to 27.5) | 18.7 (16.4 to 21.2) | 22.2 (19.9 to 24.7) | 18.3 (15.1 to 22.2) | 39.6 (35.1 to 44.8) | 50.5 (45.7 to 56.1) | 27.6 (23.9 to 31.5) |
|              |               | Iran                      | 55.8 (50.1 to 62.5) | 69.5 (62.1 to 77.8) | 24.7 (22.7 to 26.9) | 369 (32.8 to 41.5) | 44.5 (39.7 to 49.8) | 20.6 (18.7 to 22.7) | 75.3 (67.6 to 84.5) | 94.9 (85 to 107) | 26.1 (23.4 to 29) |
Table 1 (continued)

| Measure | Unit | Location          | Both  | Male  | Female | Both  | Male  | Female | Both  | Male  | Female |
|---------|------|-------------------|-------|-------|--------|-------|-------|--------|-------|-------|--------|
|         |      |                   | 1990  | 2017  | Percent change | 1990  | 2017  | Percent change | 1990  | 2017  | Percent change |
| Deaths  | Number a | Global            | 12,290 (10,793 to 14,420) | 20,655 (17,721 to 22,238) | 68.1 (14.2 to 83.0) | 5115 (4368 to 5869) | 8452 (7123 to 9162) | 65.2 (17.8 to 79.0) | 7175 (6055 to 9009) | 12,203 (10,082 to 13,629) | 70.1 (12.0 to 87.5) |
|         |      | North Africa and Middle East | 371 (231 to 648) | 1040 (706 to 1263) | 180.0 (53.3 to 257.9) | 170 (107 to 274) | 489 (332 to 558) | 187.7 (67.8 to 271.3) | 7175 (6055 to 9009) | 202 (121 to 378) | 551 (346 to 738) |
|         |      | Iran              | 91 (71 to 131) | 290 (205 to 319) | 219.2 (61.1 to 305.8) | 42 (31 to 58) | 133 (89 to 148) | 219.6 (75.8 to 301.5) | 49 (37 to 74) | 157 (111 to 176) | 218.8 (52.5 to 323.4) |
| Rate b  |      | Global            | 0.3 (0.3 to 0.3) | 0.2 (0.2 to 0.2) | −10.1 (−38.8 to −2.3) | 0.2 (0.2 to 0.2) | 0.2 (0.2 to 0.2) | −11.7 (−37.2 to −4.8) | 0.3 (0.3 to 0.4) | 0.3 (0.2 to 0.3) | −9.2 (−39.8 to 0.0) |
|         |      | North Africa and Middle East | 0.2 (0.1 to 0.3) | 0.2 (0.1 to 0.2) | 16.2 (−35.8 to 46.7) | 0.2 (0.1 to 0.3) | 0.2 (0.1 to 0.2) | 18.8 (−30.2 to 51.7) | 0.2 (0.1 to 0.3) | 0.2 (0.1 to 0.3) | 14.8 (−39.2 to 47.6) |
|         |      | Iran              | 0.3 (0.2 to 0.4) | 0.4 (0.3 to 0.4) | 27.4 (−34.3 to 60.3) | 0.3 (0.2 to 0.4) | 0.3 (0.2 to 0.4) | 28.7 (−28.6 to 61.7) | 0.3 (0.2 to 0.4) | 0.4 (0.3 to 0.4) | 26.9 (−38.1 to 66.1) |
| DALYs   | Number a | Global            | 682,944 (586,530 to 811,282) | 1,084,757 (942,878 to 1,237,344) | 58.8 (29.4 to 72.8) | 262,002 (227,343 to 302,473) | 407,529 (354,187 to 459,135) | 55.5 (28.7 to 68.1) | 420,942 (355,788 to 509,258) | 677,228 (579,371 to 780,792) | 60.9 (31.3 to 76.6) |
|         |      | North Africa and Middle East | 32,940 (24,924 to 46,413) | 90,888 (71,930 to 110,100) | 175.9 (111.4 to 210.6) | 12,541 (9482 to 17,234) | 34,807 (27,434 to 41,382) | 177.5 (111.0 to 219.3) | 20,399 (15,296 to 29,285) | 56,082 (43,493 to 69,772) |
|         |      | Iran              | 9098 (7244 to 11,463) | 26,183 (21,205 to 31,381) | 187.8 (122.2 to 222.9) | 3420 (2752 to 4296) | 9725 (7889 to 11,529) | 184.3 (120.4 to 221.1) | 5677 (4448 to 7296) | 16,458 (13,232 to 19,728) |
| Rate b  |      | Global            | 14.8 (12.8 to 17.5) | 13.3 (11.5 to 15.2) | −10.2 (−26.8 to −2.7) | 11.5 (10.0 to 13.2) | 10.1 (8.8 to 11.4) | −11.9 (−27.5 to −5.4) | 18.0 (15.2 to 21.6) | 16.3 (14.0 to 18.9) | −9.2 (−25.6 to −0.6) |
|         |      | North Africa and Middle East | 13.6 (10.3 to 19.2) | 16.1 (12.8 to 19.6) | 18.3 (−9.9 to 33.2) | 10.3 (7.8 to 14.2) | 12.0 (9.5 to 14.2) | 16.0 (−12.5 to 33.2) | 17.1 (12.8 to 24.4) | 20.6 (16.1 to 25.4) | 20.7 (−7.3 to 35.9) |
|         |      | Iran              | 23.7 (18.9 to 29.8) | 29.1 (23.6 to 34.7) | 23.1 (−5.1 to 37.1) | 178 (144 to 225) | 218 (17.6 to 25.7) | 22.4 (−5.6 to 38.2) | 29.7 (23.4 to 38.0) | 36.6 (29.4 to 43.9) | 23.4 (−3.9 to 38.9) |

---

a All ages; b Age-standardized rate per 100,000; c 1990–2017
0.8 (Table 1). The ASDR due to MS in Iran increased from 23.7 (18.9 to 29.8) per 100,000 population in 1990 to 29.1 (23.6 to 34.7) in 2017, with an average annual percentage change of 0.7. The females to male's ratio of ASDR was 1.6 in both 1990 and 2017 (Table 1). The evaluation of the DALYs rate age trend showed that an upward trend began at the age of 20 with a relatively steep slope and continued to peak until the age of 45. Afterwards, it declined by a slight downward slope and from the age of 55 it began to decline and continued so until death (Fig. 1). The MS related ASMR in Iran increased from 0.3 (0.2 to 0.4) per 100,000 population in 1990 to 0.4 (0.3 to 0.4) in 2017, with an average annual percentage change of 0.9 (Table 1). From the age of 20 to 55, mortality rate was always higher among females. However, the mortality rate in people over 55 years of age was higher among males (Fig. 3). ASMR and ASDR were respectively 1.3 and 1.7 times greater than the level expected in 2017 given the SDI level (Table 3).
The ASIRs of MS attributable to smoking were 2.4 and 2.5 per 100,000 people in 1990 and 2017, respectively. Its male-to-female ratio was 3.0 in 1990 and 3.1 in 2017.

Discussion

The results of this study showed that the age-standardized rates of all estimates for MS in 2017 were higher than in 1990. In addition, from the beginning to the end of the study all of the estimates were higher in women. Moreover, the highest incidence rate was among the 25–29 years age group while the highest DALY rate was among 45–49 year olds.

This study shows that the incidence and prevalence and DALY rates have increased in the last 10 years. A review study by Heydarpour et al. was conducted on population-based researches in the Middle East and North Africa. It indicated an upward trend in the prevalence of the disease in Tehran from 2008 to 2011 and also showed a rising incidence trend in Tehran in the last two decades. The ASIR of MS in Tehran increased from 0.68 in 1989 to 5.68 in 2005 [12]. In addition to Tehran, population-based studies in Isfahan revealed a general increase in the incidence and prevalence of the disease in the last decade, where ASPR increased from 35.5 per 100,000 people in 2006 to 85.8 in 2013 [12]. This finding was consistent with our study’s findings. On the other hand, a study by Mansouri et al. divided the whole world into seven major geographic regions and examined the incidence and prevalence of MS in these areas. Their results indicated that the incidence and prevalence trends of MS had decreased in 5 of the regions, which included Iran and the Middle East. Latin America and the Caribbean were the only 2 regions that showed increasing trends of incidence and prevalence in recent years. Lack of vitamin D intake and genetic risk factors have been cited as the possible causes of this increasing trend [6]. A longitudinal study from 2001 to 2013 evaluating the prevalence and trends of vitamin D deficiency in Iran showed that although the prevalence of vitamin D inadequacy (deficiency and insufficiency) decreased. The prevalence of vitamin D deficiency and insufficiency was still high in 2001, 2007, and 2013 (62.0, 57.9, and 53.9%). Mentioned rates of vitamin D inadequacy could be an essential cause.

Table 2 Decomposition analysis of factors affecting number of incident cases of Multiple Sclerosis during 1990 to 2017, Iran

| Sex    | % 1990–2017 incident case change | Overall change |
|--------|---------------------------------|----------------|
|        | Population growth | Age structure change | Incidence rate change | Overall change |
| Both   | 42.0%              | 26.2%              | 34.1%              | 102.3%          |
| Male   | 41.4%              | 38.2%              | 24.2%              | 103.8%          |
| Female | 42.7%              | 18.9%              | 40.0%              | 101.6%          |

Fig. 3 Comparison of each measure’s rate by age group and sex, 1990 vs 2017

Table 2 Decomposition analysis of factors affecting number of incident cases of Multiple Sclerosis during 1990 to 2017, Iran
Table 3  Observed and expected burden of Multiple Sclerosis in 1990 and 2017 by sex

| Measure | Unit | Both | 1990 | 2017 | O/E ratio | O | E | O/E ratio | O | E | O/E ratio | O | E | O/E ratio |
|---------|------|------|------|------|-----------|---|---|-----------|---|---|-----------|---|---|-----------|
| Deaths  | Number | 91   | 69   | 1.3  | 290       | 290| 1.0| 42        | 32 | 1.3 | 133       | 130| 1.0| 49        | 37 | 1.3 | 157       | 159| 1.0 |
| Rate    |       | 0.3  | 0.2  | 1.5  | 0.4       | 0.3| 1.3| 0.3       | 0.2| 1.5 | 0.3       | 0.3| 1.0| 0.3       | 0.2| 1.5 | 0.4       | 0.4| 1.0 |
| DALYs   | Number | 9098 | 3621 | 2.5  | 26,183    | 14,947| 1.8| 3420      | 1485| 2.3 | 9725      | 6121| 1.6| 5677      | 2116| 2.7 | 16,458    | 8783| 1.9 |
| Rate    |       | 23.7 | 7.9  | 3.0  | 29.1      | 16.8| 1.7| 17.8      | 6.7 | 2.7 | 21.8      | 13.8| 1.6| 29.7      | 9.2 | 3.2 | 36.6      | 19.8| 1.8 |

a  All ages; b Age-standardized rate per 100,000
O: Observed; E Expected
of increasing trends of MS rates in Iran [20]. Since Heydarpour's study reported the results of population-based studies, it has more reliable results compared to Mansouri's study, which in order to estimate measures was based on modeling. This review study showed the highest ASPR to be in Tehran and Isfahan with 50.4 and 31.5 per 100,000 people, respectively [12]. A study by Eskandarieh et al. examined the status of MS in southern, eastern and Southeast Asia. It revealed that some Asian countries, including Iran and Japan, had reported an increasing prevalence of MS in the last decade. For instance, according to the Iranian Ministry of Health's report, the prevalence of MS in 2011 in Iran was 45 per 100,000 people and 54.5 in 2013 [21]. In our study in 2017, this number had increased to 69.5 per 100,000 population.

One of the possible causes of this upward trend is the shift to a western lifestyle, smoking, UV-protection and low levels of vitamin D [12]. Other causes of the increasing incidence and prevalence trends of MS can be the unwanted side effects of increased health and the development of health facilities that have been developed under the heading of "hygiene theory". The theory states that by increasing health, vaccination and the use of antibiotics in developed countries during the past decades, the immune system has changed improperly and people are now prone to autoimmune diseases [6]. In addition to the hygiene theory, the increasing number of diagnostic tools in recent years can lead to an increase in ASIR. The first MRI device arrived in Iran in 1990, after which the number of these devices slowly increased until 1995. And since 1999, the number of these devices has multiplied. In 2005 there were 93 devices in Iran, and the number of MRI devices per one million population was 1.93 in 2005 and 3.5 in 2016 [22, 23]. Furthermore, timely and advanced health care in developed countries can lead to an increase in the survival of patients and thus an increase in the ASPR of the disease [4, 6]. The Global Atlas of MS has shown that access to specialist services in low-income countries is 0.03 per 100,000 population and 3.6 in high-income countries. The number of Magnetic Resonance Imaging devices available in the world is 0.42 per 100,000 people. This number is 1.6 in high-income countries, 0.4 in lower-middle-income countries and 0.01 in low-income countries [24]. So, we can state that more diagnostic tools and facilities can increase the chance of MS detection.

In our study, the female-to-male ratios of ASIR and APR in 2017 were 1.9 and 2.1, respectively. This finding was in line with other studies conducted in Denmark, France, Australia and Norway, which also revealed an increase in the incidence and prevalence rates among females [3]. The searches conducted in the study by Tolou-ghamari et al., who examined the geo-epidemiological differences in MS in Iran and other Middle Eastern countries, showed that the epidemiology of this disease was changing and its incidence among the female population in recent years had doubled [25]. These findings are in line with our study's findings. The environmental factors that are likely to contribute to the increased incidence of MS in women include increased cigarette smoking among women, changes in lactation patterns, increased obesity, increased gestational age, use of oral contraceptives, decreased physical activity, and increased stress [3, 4].

In our study, the 25–29 years age group had the highest incidence rates, and in the study by Eskandarieh et al., the highest prevalence rate was among 24–29 year-olds. These findings are consistent with our study's findings [11]. The GBD 2017 study showed that the DALYs rate was highest in the sixth decade of life [15]; since it usually affects people from an early age and survival has also increased among these patients, leading to an increase in DALYs rate. In our study, ASDR reached its highest level in the late fifties, followed by a downward trend until the end of the patients' lives. The DALY's trend for MS has a different pattern from other neurological diseases. Although the incidence rate of MS is very low, it causes a lot of DALYs because it occurs at an early age [26]. New changes in the sex, race, and nationality of MS patients suggest the role of environmental factors in the development of this disease. The most important risk factors include infection with the Epstein bar virus, which starts from the stomach and spreads to the brain. Other risk factors include smoking, lack of sunlight, diet, obesity and gastric microorganisms. More than 200 alleles in the human genome have been identified as risk factors for MS and that genetics is a known risk factor for this disease [27].

This study had several strengths and limitations. One strength was that we used several databases including MS registry and death registry system's data, then we used modeling methods for filling the gaps and calculating uncertainty, so we could cover the incompleteness of registry systems. One of the limitations of this study was the lack of categorization of results based on the different clinical courses of multiple sclerosis, which is due to the incompleteness of current registry systems. Based on clinical courses of the disease, MS is classified into four different types [28].

**Conclusion**

In conclusion, the results of this study showed that during the study period, all MS age-standardized rates in Iran had been increasing. In addition, the sex ratio in all measures had always been higher among females. The geographical distribution of all MS measures also followed
a specific pattern, with the highest rates observed in the north and northwestern regions of the country, and the lowest rates observed in the east, south and southeastern parts of the country. Our findings can help policymakers and health planners to design and communicate their plans and have a better resource allocation at provincial levels, depending on the incidence and prevalence of the growing numbers of MS patients in Iran.

Abbreviations
MS: Multiple Sclerosis; DALYs: Disability Adjusted Life Years; GBD: Global Burden of Disease study; ASIR: Age-Standardized Incidence Rate; ASPR: Age-Standardized Prevalence Rate; ASDR: Age-Standardized Mortality Rate; CNS: Central Nervous System; YLLs: Years of Life Lost; YLDs: Years Lived with Disability; ICD: International Classification of Diseases; SDI: sociodemographic index; MIR: Mortality-to-Incidence Ratio.

Acknowledgments
The authors would like to thank the Institute for Health Metrics and Evaluation team for providing the methodology and results of the Global Burden of Disease study. The authors would also like to thank the Non-Communicable Diseases Research Center’s staff of the Endocrinology and Metabolism Population Sciences Institute of Tehran University of Medical Sciences for their wholehearted cooperation.

Authors’ contributions
NF: Writing First Draft, Validation. SM: Analysis, Visualization, Validation. FM1, NR: Review & Editing. MM: Validation. SF: Project Administration, Resources. EH, FM2, EF: Investigation, Review & Editing. MS, MI, AM, MN: Data Resources, Investigation, Review & Editing. FF: Conceptualization, Investigation, Review & Editing, Supervision. The author(s) read and approved the final manuscript.

Funding
The Global Burden of Diseases (GBDs) study received funding from the Bill and Melinda Gates Foundation. Funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or final approval of the manuscript; and decision to submit the manuscript for publication.

Availability of data and materials
All data generated or analyzed during this study are publicly available dataset. MS data analyzed in this study are publicly available in the GBD data tool: (https://gbd2017.healthdata.org/gbd-compare).

Declarations
Ethics approval and consent to participate
No individual data was reported in this paper and the information is based on an aggregated pre-existing online data. All the data included in this study are publically available on the GBD Compare tool (https://gbd2017.healthdata.org/gbd-compare). Therefore, the need for ethical approval is unnecessary in this study.

Consent for publication
Not applicable.

Competing interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Author details
1Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran. 2Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran. 3Department of Epidemiology and Biostatistics, Tehran University of Medical Sciences, Tehran, Iran. 4Department of Internal Medicine, Tohid Hospital, Kurdistan University of Medical Sciences, Sanandaj, Iran. 5Department of Neurology, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran. 6Preventive Medicine and Public Health Research Center, Iran University of Medical Sciences, Tehran, Iran. 7Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.

Received: 30 September 2020 Accepted: 4 October 2021
Published online: 15 October 2021

References
1. Stenager E. A global perspective on the burden of multiple sclerosis. Lancet Neurol. 2019.
2. Ameeza L, Rivas E, Joseph S, Zhang J, Liu L. Multiple sclerosis mortality by race/ethnicity, age, sex, and time period in the United States, 1999–2015. Neuroepidemiology. 2018;50(1–2):35–40.
3. Leray E, Moreau T, Fromont A, Edan G. Epidemiology of multiple sclerosis. Rev Neurol. 2016;172(1):3–13.
4. Wallin MT, Culpepper WJ, Nichols E, Bhutta ZA, Gebrehiwot TT, Hay SI, et al. Global, regional, and national burden of multiple sclerosis 1990–2016: a systematic analysis for the global burden of disease study 2016. Lancet Neurol. 2019;18(3):269–85.
5. Goldenberg MM. Multiple sclerosis review. Pharmacy and Therapeutics. 2012;37(3):175.
6. Mansouri S, Zayeri F. Global and regional trends of multiple sclerosis disability-adjusted life years rates: a 25-year assessment. Neuroepidemiology. 2019;52(1–2):17–24.
7. Li R, Patterson KR, Bar-Or A. Reassessing B cell contributions in multiple sclerosis. Nat Immunol. 2018;19(7):696–707.
8. Simpson S, Blizzard L, Otahal P, Van der Mei I, Taylor B. Latitude is significantly associated with the prevalence of multiple sclerosis: a meta-analysis. J Neurol Neurosurg Psychiatry. 2011;82(10):1132–41.
9. Riccio P, Rossano R. Nutrition facts in multiple sclerosis. ASN neuro. 2015;7(1):1759091414568185.
10. Kingwell E, Marriott JJ, Jetté N, Pringle MJ, Mihailidis A, et al. Incidence and prevalence of multiple sclerosis in Europe: a systematic review. BMC Neurol. 2013;13(1):128.
11. Eskandarieh S, Heydarpour P, Ethami S-R, Sahraian MA. Prevalence and incidence of multiple sclerosis in Tehran, Iran. Iran J Public Health. 2017;46(5):699.
12. Heydarpour P, Khoshkish S, Abtahi S, Moradi-Lakeh M, Sahraian MA. Multiple sclerosis epidemiology in Middle East and North Africa: a systematic review and meta-analysis. Neuroepidemiology. 2015;44(4):232–44.
13. Hankirishnan S, Jeemon P, Mini G, Thanappan K, Selvajanan K, Yadav P. GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. 2018.
14. James S, Abate D, Abate K, Aboy S, Abbafati C, Abbasi N, et al. GBD 2017 disease and injury incidence and prevalence collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the global burden of disease study 2017. Lancet. 2018;392(10159):1789–858.
15. Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1859–922.
16. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the global burden of disease study 2017. Lancet. 2018;392(10159):1736–788.
17. Global, regional, and national age-sex-specific mortality and life expectancy, 1950–2017: a systematic analysis for the global burden of disease study 2017. Lancet. 2018;392(10159):1684–1735.
18. Gilat T, Zusius A, Leichman G, Delpe G, Pavlotzky M, Grossman A, et al. A comparative study of metronidazole and sulfasalazine in active, not
severe, ulcerative colitis. An Israeli multicenter trial. J Clin Gastroenterol. 1987;9(4):415–7.
19. Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, Brenner H, et al. Global, regional, and National Cancer Incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 Cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA oncology. 2017;3(4):524–48.
20. Khosravi-Boroujeni H, Sarrafzadegan N, Sadeghi M, Roohafza H, Ng S-K, Pourmogaddas A, et al. Prevalence and trends of vitamin D deficiency among Iranian adults: a longitudinal study from 2001–2013. J Nutr Sci Vitaminol. 2017;63(5):284–90.
21. Etemadifar M, Ijadi S, Nikkereish A, Sharifian M, Sahraian MA, Nasr Z. Estimated prevalence and incidence of multiple sclerosis in Iran. Eur Neurol. 2014;72(5–6):370–4.
22. Palesh M, Fredrikson S, Jamshidi H, Jonsson PM, Tomson G. Diffusion of magnetic resonance imaging in Iran. Int J Technol Assess Health Care. 2007;23(2):278.
23. Haji Aghajani M, Hashemi H, Haghdoost A, Noori Hekmat S, Janbabaee G, Maher A, et al. Distribution of major medical equipment in Iran in 2016 and the estimation of needs in 2026. Iran J Epidemiol. 2018;13:37–47.
24. Browne P, Chandraratna D, Angood C, Tremlett H, Baker C, Taylor BV, et al. Atlas of multiple sclerosis 2013: a growing global problem with widespread inequity. Neurology. 2014;83(11):1022–4.
25. Tolou-Ghamari Z. A review of geoepidemiological differences of multiple sclerosis in Iran and other Middle East countries. Archives of Neuroscience. 2015;2(3).
26. Chung S-E, Cheong H-K, Park J-H, Kim HJ. Burden of disease of multiple sclerosis in Korea. Epidemiol Health. 2012;34.
27. Baranzini SE, Oksenberg JR. The genetics of multiple sclerosis: from 0 to 200 in 50 years. Trends Genet. 2017;33(12):960–70.
28. Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83(3):278–86.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.